Genentech and Ventana Get FDA Approval on Treatment for Bladder Cancer

The U.S. Food and Drug Administration  approved Tecentriq (atezolizumab) on May 18, 2018 to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients’ tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq..

Continue reading